Literature DB >> 10438343

Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment.

R S Fritz1, F G Hayden, D P Calfee, L M Cass, A W Peng, W G Alvord, W Strober, S E Straus.   

Abstract

The local immune response to influenza virus infection was characterized by determining cytokine and chemokine levels in serial nasal lavage fluid samples from 15 volunteers experimentally infected with influenza A/Texas/36/91 (H1N1). The study was part of a randomized double-blind placebo-controlled trial to determine the prophylactic effect of intravenous zanamivir (600 mg 2x/day for 5 days), a highly selective inhibitor of influenza A and B virus neuraminidases, on the clinical symptoms of influenza infection. Nasal lavage fluid levels of interleukin (IL)-6, tumor necrosis factor-alpha, interferon-gamma, IL-10, monocyte chemotactic protein-1, and macrophage inflammatory protein-1alpha and -1beta increased in response to influenza virus infection and correlated statistically with the magnitude and time course of the symptoms. Treatment with zanamivir prevented the infection and abrogated the local cytokine and chemokine responses. These results reveal a complex interplay of cytokines and chemokines in the development of symptoms and resolution of influenza.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438343     DOI: 10.1086/314938

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  81 in total

Review 1.  Molecular machinations: chemokine signals in host-pathogen interactions.

Authors:  S W Chensue
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Anti-tumor necrosis factor therapy and influenza: keeping it in perspective.

Authors:  Matt Shale; Markus Czub; Gilaad G Kaplan; Remo Panaccione; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

3.  Studies of "natural" remedies for the common cold: pitfalls and pratfalls.

Authors:  Ronald B Turner
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

4.  1, 8-Cineol Protect Against Influenza-Virus-Induced Pneumonia in Mice.

Authors:  Yun Li; Yanni Lai; Yao Wang; Ni Liu; Fengxue Zhang; Peiping Xu
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

Review 5.  Crossing the scale from within-host infection dynamics to between-host transmission fitness: a discussion of current assumptions and knowledge.

Authors:  Andreas Handel; Pejman Rohani
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-08-19       Impact factor: 6.237

6.  ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.

Authors:  J H Beigel
Journal:  Drugs Future       Date:  2010-05       Impact factor: 0.148

Review 7.  Immunogenetics of seasonal influenza vaccine response.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

8.  Exploring the role of the immune response in preventing antibiotic resistance.

Authors:  Andreas Handel; Elisa Margolis; Bruce R Levin
Journal:  J Theor Biol       Date:  2008-11-08       Impact factor: 2.691

9.  Risk factors of influenza transmission in households.

Authors:  Cécile Viboud; Pierre-Yves Boëlle; Simon Cauchemez; Audrey Lavenu; Alain-Jacques Valleron; Antoine Flahault; Fabrice Carrat
Journal:  Br J Gen Pract       Date:  2004-09       Impact factor: 5.386

10.  Viral upper respiratory tract infection and otitis media complication in young children.

Authors:  Tasnee Chonmaitree; Krystal Revai; James J Grady; Audra Clos; Janak A Patel; Sangeeta Nair; Jiang Fan; Kelly J Henrickson
Journal:  Clin Infect Dis       Date:  2008-03-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.